Advertisement

Topics

Companies Related to "Global Development secures future drug candidate development CollegeHill" [Most Relevant Company Matches] RSS

16:43 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Global Development secures future drug candidate development CollegeHill" found in our extensive corporate database of over 50,000 company records.

Showing "Global Development secures future drug candidate development CollegeHill" Companies 1–25 of 13,000+

Relevant

ACTAR AB

Actar is a biomedical company which builds the bridge from academic research to drug development. Actar is located at Karolinska Institutet and has eight employees. Actar identifies drug targets from Karolinska Institutet and other top Nordic Universities and performs drug development associated with the target to develop a candidate drug. The work is executed through high throughput screening of ...


Formula Pharmaceuticals Inc.

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01 is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other canc...

Formula Pharmaceuticals

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other can...


Formula Pharmaceuticals, Inc.

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other can...

Depomed, Inc.

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Produ...

Viventia Biotech Inc

Viventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s lead product candidate Proxinium™ continues on an aggressive clinical development schedule. Viventia has initiated a Phase II North American clinical trial and concurrently commenced a pivotal Phas...

Receptron Incorporated

Receptron has a novel and proprietary position in drug discovery and development. The company's original focus was on diabetes but now has expanded to include a diverse portfolio of research and development projects in the areas of endocrinology (growth hormone), hematology (EPO, TPO), and immunology. Receptron's proprietary technology also allows for future drug development in the cardiovascular ...

Teva Pharmaceutical Industries Ltd. & OncoGenex Pharmaceuticals, Inc.

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the le...

Eribis Pharmaceuticals AB

Eribis Pharmaceuticals is focused on the development of novel drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, as well as surgical preconditioning. The company has unique competence in the development of peptides for pharmacological use. Eribis' novel peptide candidate drug represents a new drug category aimed at meeting the market need for new and ...

DOV Pharmaceutical

We are a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, cardiovascular and urological disorders. We have five product candidates in clinical trials addressing therapeutic indications with significant unmet needs. Our product candidate for insomnia is currently in Phase III clinical trials and o...

ACADIA Pharmaceuticals Inc.

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is currently developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indi...

Daewoong Pharmaceutical Co., Ltd.

Established in 1945, Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2010. Daewoong has maintained a steady growth rate in the double digits and has paid surplus dividends for the last 40 years. In addition to its product portfolio, which includes 10 blockbuster products, Daewoong has built stro...

RegeneRx Pharmaceuticals, Inc.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among oth...

RegeneRx Biopharmaceuticals, Inc. and Lee’s Pharmaceutical Holdings Ltd.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among oth...

BMI

BMI was established in the summer of 2004 with a strong portfolio of early stage innovations transferred from Medinnova and from Oslo Research Park. Today, BMI is focusing on the development of drugs based on compounds that interfere with the signal mediator serotonin. In particular, BMI is currently in clinical phase II with GSK's 5-HT4 antagonist piboserod for the treatment of heart failure. D...

Zalicus Inc

Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo™ (hydromorphone HCl) extended-release tablets (marketed by Covidien), for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended per...

Accium BioSciences, Inc.

Accium BioSciences operates the first fully commercial and independent Accelerator Mass Spectrometry (AMS) analytical facility in the U.S. The facility features a high throughput, custom designed 1.5 SDH-1 Pelletron Accelerator Mass Spectrometer dedicated to drug development services. We provide a portfolio of AMS-based bioanalytical services that address challenging problems in drug developm...

Locum International

The Locum International Group is a limited Research Association comprising of :(a.) A Pharmaceutical Research and Development Company with extensive experience in product development, manufacturing, regulatory affairs and drug technology and know-how sales in the global market place.(b.) A Pioneering Drug Development Association IAGIM(c.) A Specialist Pharmaceutical Publishing House.The Internatio...

Raven biotechnologies, inc.

Raven's approach creates the optimal starting point for developing a new drug with an increased probability of success in the clinic, within a substantially compressed time frame for drug lead development. The heart of Raven's technical approach is a unique focus on the cell surface—the primary docking point for drugs and diseases—which enables rapid identification of disease-specific antigens...

AmericasDoctor

At Essential Group, Inc we are excited about the success of our Essential CRO and Essential Patient Recruitment services. We have made a strategic decision to focus our operations and future growth on these two primary clinical development services. AmericasDoctor clinical development services will change to concentrate on site training, education and development on a global basis. By mid year 200...

Emergent BioSolutions

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterroris...

PharmaNet Development Group

PharmaNet Development Group, a global, drug development services company, provides expertise to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet companies offer clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical develop...

Telik

Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. Our most advanced development candidate is TELCYTA™ (TLK286), a novel cancer cell-activated chemotherapeutic currently in four Phase 3 registration trials in advanced ovarian cancer and non-small...

Generon (Shanghai) Corporation Ltd.

Generon (Shanghai) Corporation Ltd. is a biotechnology company based in China with a mission to develop innovative biological therapies for patients in China and around the world. F-627 is a newer generation recombinant human granulocyte colony-stimulating factor (G-CSF) that helps the cancer patients to recover from chemotherapy induced neutropenia, a pot...

Ensemble Therapeutics Corporation

Based in Cambridge, MA, Ensemble Therapeutics is deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Ensemble is leveraging its macrocycle drug discovery expertise to fuel its proprietary drug candidate pipeline while also pursuing collaborations with pharmaceutical partners. Ensemble has ...


More From BioPortfolio on "Global Development secures future drug candidate development CollegeHill"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks